Table 2.
ID# | Rx Dose (Gy) |
Maximum Cord Dose (Gy) |
Age at SRS (weeks) |
Follow-up (weeks) |
Latency (weeks) |
---|---|---|---|---|---|
1 | 12 | 12.9 | 44 | 56 | NA* |
2 | 16 | 16.7 | 44 | 57 | NA* |
3 | 16 | 16.9 | 42 | 53 | NA* |
4 | 16 | 17.1 | 45 | 53 | NA* |
5 | 16 | 16.9 | 47 | 54 | NA* |
6 | 16 | 16.9 | 45 | 53 | NA* |
7 | 18 | 18.8 | 43 | 58 | NA* |
8 | 18 | 19 | 40 | 53 | NA* |
9 | 18 | 19 | 45 | 53 | NA* |
10 | 18 | 18.8 | 47 | 53 | NA* |
11 | 18 | 19 | 43 | 27 | 23 |
12 | 20 | 20.9 | 43 | 75 | NA* |
13 | 20 | 21.1 | 42 | 16 | 15 |
14 | 20 | 20.9 | 43 | 53 | 35 |
15 | 20 | 21.1 | 40 | 20 | 18 |
16 | 20 | 21.1 | 40 | 27 | 20 |
17 | 22 | 23.2 | 43 | 11 | 10 |
18 | 22 | 23.0 | 41 | 12 | 10 |
19 | 22 | 22.7 | 43 | 15 | 13 |
20 | 22 | 23.0 | 38 | 18 | 18 |
21 | 24 | 25.6 | 42 | 33 | 13 |
22 | 24 | 25.3 | 44 | 31 | 14 |
23 | 24 | 25.3 | 43 | 15 | 14 |
24 | 24 | 24.8 | 41 | 14 | 12 |
25 | 36 | 38.4 | 44 | 25 | 19 |
26 | 47 | 49.8 | 40 | 8 | NA* |
No motor neurologic deficits were observed in stated follow-up period.